Beclomethasone Dipropionate

證據等級: L5

預測適應症: 1 個

Beclomethasone Dipropionate: From Asthma to Atopic Eczema

One-Sentence Summary

Beclomethasone Dipropionate (BDP) is a potent synthetic glucocorticoid currently used for inhaled asthma management and intranasal treatment of allergic rhinitis. The TxGNN model predicts it may be effective for atopic eczema — specifically via oral administration in refractory cases — with 0 registered clinical trials and 18 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Asthma (inhaled); Allergic rhinitis (intranasal)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.41%
Evidence Level	L3
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, formal mechanism of action data is not available in the structured dataset. Based on established pharmacological knowledge, Beclomethasone Dipropionate is a high-potency synthetic glucocorticoid. It acts by binding intracellular glucocorticoid receptors (GR), which in turn suppresses the NF-κB transcription factor and downregulates pro-inflammatory Th2 cytokines — including IL-4, IL-13, and IL-31.

Atopic eczema is driven by precisely this Th2-skewed immune dysregulation, combined with impaired skin barrier function. The same cytokine cascade that BDP suppresses (IL-4, IL-13, IL-31) is responsible for the hallmark features of atopic eczema: intense pruritus, skin inflammation, and barrier breakdown. This mechanistic overlap makes the TxGNN prediction biologically well-grounded.

It is worth noting that topical corticosteroids (TCS) are already the established first-line treatment for atopic eczema — the novel repurposing angle here is specifically oral BDP for refractory, difficult-to-treat atopic eczema. This route potentially avoids heavier systemic immunosuppressants (e.g., cyclosporine) while leveraging BDP’s gut-level immune modulation. Early clinical evidence from the 1980s–1990s demonstrated feasibility, though this administration route is not currently approved in Canada.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6434024	1984	RCT	British Medical Journal	Double-blind placebo-controlled crossover trial in 26 children with severe atopic eczema; combined oral + nasal BDP produced significant improvement over placebo across 4 weeks, with only mild adrenal suppression and no adverse effects observed
1476023	1992	Clinical Case Series	Acta Dermato-Venereologica	Oral BDP (mean 1,000 µg/day) achieved stable disease control in 10/14 children with difficult atopic dermatitis; growth deceleration noted at maintenance dose, raising pediatric safety considerations
30911861	2019	Formulation Study	AAPS PharmSciTech	Development and characterization of BDP-loaded mixed micelles incorporated into hydrogel for dermal delivery; sub-chronic dermatitis animal model confirms enhanced dermal BDP bioavailability via novel formulation
14522624	2003	Clinical Safety Study	Journal of Dermatological Treatment	Assessed effects of intensive steroid wet-wrap therapy on short-term growth and bone turnover in 8 prepubertal children with atopic eczema; provides critical safety reference data for corticosteroid-based atopic eczema regimens
8765824	1996	Clinical Study	Journal of Allergy and Clinical Immunology	Topical steroids in atopic dermatitis may paradoxically enhance in vitro IgE production; underscores the need for careful monitoring and the limitations of long-term corticosteroid use in atopic eczema
19874229	2009	Comparative Animal Study	Immunopharmacology and Immunotoxicology	Head-to-head comparison of BDP vs mometasone furoate in murine ear edema model; mometasone showed superior local anti-inflammatory potency with lower systemic HPA axis suppression relative to BDP
19571596	2009	Review	Neuroimmunomodulation	Reviews HPA axis suppression risk from intranasal corticosteroids in patients with comorbid asthma and atopic dermatitis; directly relevant to systemic safety monitoring for patients on multi-route BDP
9463794	1998	Review	Drugs	Comprehensive review of mometasone (a 16α-methyl analogue of BDP) for inflammatory dermatoses including atopic dermatitis; confirms class-level efficacy of glucocorticoids in atopic eczema and provides a reference benchmark for BDP
11488426	2001	Review	Japanese Journal of Pharmacology	Broad review of glucocorticoids — specifically naming BDP and fluticasone — for allergic diseases; confirms mechanistic rationale and established anti-inflammatory efficacy across the Th2 disease spectrum
37023229	2023	Computational Study	Journal of Chemical Information and Modeling	Knowledge graph–based drug repurposing framework (DrugRep-KG) that validates computational prediction methodology; provides methodological context for interpreting TxGNN’s BDP–atopic eczema association

Canada Market Information

Beclomethasone Dipropionate currently has no Drug Identification Numbers (DINs) on record and is not marketed in Canada under this active ingredient profile. No licensed products are available for review.

Safety Considerations

Please refer to the package insert for safety information.

Note: Formal safety data (warnings, contraindications, and drug interactions) were not available in this evidence pack. Key known class-level concerns for glucocorticoids include HPA axis suppression, growth retardation in children, and adrenal suppression — particularly relevant given the oral route being explored.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A 1984 double-blind RCT and a 1992 clinical case series provide early proof-of-concept for oral BDP in refractory atopic eczema, and the mechanistic rationale is strong; however, the absence of modern clinical trials, zero DIN registrations in Canada, and unresolved safety data gaps mean this candidate requires significant further validation before advancing.

To proceed, the following is needed:

Retrieve and review the full prescribing information (package insert) to formally document warnings, contraindications, and drug interactions
Assess HPA axis suppression risk and growth impact at oral doses required for atopic eczema, particularly in pediatric patients
Evaluate the current clinical landscape: with dupilumab (IL-4/IL-13 blockade) now approved in Canada, determine whether an unmet need for oral BDP still exists in refractory atopic eczema
Conduct a systematic literature search for any post-1992 clinical data on oral BDP in atopic dermatitis
Define a regulatory pathway for a potential new DIN submission in Canada if evidence is deemed sufficient
Design a prospective pilot study protocol with growth monitoring and cortisol surveillance if a clinical investigation is planned
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.